ProMIS Q3 net loss $6.0M vs $1.2M YoY; cash down to $4.0M; CEO change and $7.4M PIPE closed

ProMIS Neurosciences Inc.

2022-Q3 EPS reported -$1.51

Net loss of $6.0M for Q3 2022, up from $1.2M in Q3 2021; R&D expenses rose to $4.6M from $0.8M.
Cash and equivalents $4.0M at Sep 30, 2022, down from $17.0M at Dec 31, 2021; Oct 2022 PIPE netted $6.4M.
Gail Farfel appointed CEO effective Sep 19, 2022; co-founder Eugene Williams remains Chairman.
IND submission for Alzheimer's candidate PMN310 progressing; first subject enrollment expected H1 2023.
ALS candidate PMN267 and MSA candidate PMN442 advancing; vaccine program ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProMIS Neurosciences Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $6.0 million.

Period: the third quarter ended September 30, 2022
Net income: Net loss was $6.0 million
Result: reported results

Exact text from the filing

Net loss was $6.0 million for the third quarter ended September 30, 2022, compared to $1.2 million for the same period in 2021.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117650

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.